NexImmune Past Earnings Performance

Past criteria checks 0/6

NexImmune's earnings have been declining at an average annual rate of -2.7%, while the Biotechs industry saw earnings growing at 19.1% annually.

Key information

-2.7%

Earnings growth rate

75.8%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-2,960.7%
Net Margin	n/a
Last Earnings Update	30 Jun 2024

Recent past performance updates

No updates

Recent updates

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Sep 07

Neximmune GAAP EPS of -$0.69 misses by $0.01

Aug 15

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

Jul 14

NexImmune: Selling For Under Cash Value

May 31

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

May 26

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Dec 19

Revenue & Expenses Breakdown

How NexImmune makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:NEXI Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	-21	11	6
31 Mar 24	-26	11	11
31 Dec 23	-32	13	16
30 Sep 23	-44	14	30
30 Jun 23	-49	14	35
31 Mar 23	-57	15	42
31 Dec 22	-63	16	47
30 Sep 22	-61	16	45
30 Jun 22	-61	16	46
31 Mar 22	-57	16	42
31 Dec 21	-51	16	37
30 Sep 21	-45	15	30
30 Jun 21	-39	14	23
31 Mar 21	-35	12	19
31 Dec 20	-33	10	18
30 Sep 20	-30	9	17
31 Dec 19	-23	6	15

Quality Earnings: NEXI is currently unprofitable.

Growing Profit Margin: NEXI is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NEXI is unprofitable, and losses have increased over the past 5 years at a rate of 2.7% per year.

Accelerating Growth: Unable to compare NEXI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).

Return on Equity

High ROE: NEXI has a negative Return on Equity (-2960.7%), as it is currently unprofitable.

NexImmune Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

The Nasdaq Stock Market to Delist Common Stock of NexImmune

Nasdaq Determines to Delist NexImmune Shares of Common Stock

Nasdaq Determines to Delist NexImmune Shares of Common Stock

NexImmune, Inc. announced delayed 10-Q filing

NexImmune, Inc. announced delayed annual 10-K filing

High number of new directors

NexImmune, Inc. has completed a Follow-on Equity Offering in the amount of $3.672009 million.

NexImmune Receives Notice from Nasdaq Pursuant to Nasdaq Listing Rule 5101

NexImmune, Inc. announced delayed 10-Q filing

NexImmune Regains Compliance with the Minimum Closing Bid Price Requirement

NexImmune, Inc. Approves 1 for 25 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023

NexImmune, Inc. Announces John Trainer, Chief Financial Officer to Depart, Effective September 2, 2023

New major risk - Financial position

Neximmune Announces Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-Hsct Aml At the American Society of Clinical Oncology 2023 Annual Meeting

Independent Chairman of the Board recently bought US$164k worth of stock

Price target decreased by 30% to US$2.43

High number of new directors

Independent Chairman of the Board recently bought US$96k worth of stock

Price target decreased to US$2.43

High number of new directors

NexImmune Receives Deficiency Letter from the Listing Qualifications Department of Nasdaq

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Neximmune GAAP EPS of -$0.69 misses by $0.01

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune, Inc.(NasdaqGM:NEXI) dropped from Russell 2500 Value Index

Independent Director recently bought US$298k worth of stock

Price target decreased to US$14.75

NexImmune: Selling For Under Cash Value

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

NexImmune Inc. Appoints Leena Gandhi to Board of Directors as a Non-Executive Director

NexImmune, Inc., Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Neximmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center

Neximmune, Inc. Promotes Mathias Oelke, Ph.D., to Chief Scientific Officer

NexImmune, Inc. Announces Management Changes

Independent Director exercised options to buy US$338k worth of stock.

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Independent Director has left the company

NexImmune, Inc. has completed an IPO in the amount of $110.007 million.

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies